JAK inhibitor

Dont cross signal on city street
Biotech

Incyte ditches phase 1-stage JAK inhibitor for next-gen options

Incyte has ditched a JAK2 inhibitor in phase 1 development for a rare blood cancer in favor of “next-generation” replacements.
Marissa Russo Jul 28, 2026 10:32am
dynamic arrows moving up

Priovant will move brepocitinib to phase 3 after midstage win

Feb 6, 2026 7:00am
pipeline valve pipe flow water tap

Prelude loses CMO, pauses SMARCA2 degraders, scores Incyte cash

Nov 4, 2025 9:40am
An arrow incrementally going up stairs before pointing straight up Blue background

Roivant reports phase 3 autoimmune win for ex-Pfizer asset

Sep 17, 2025 7:00am
Photo of a final puzzle piece about to fit into a puzzle

Sanofi signs €545M deal to explore Formation’s JAK/SYK inhibitor

Jun 23, 2025 9:47am
business targets illustration

Accropeutics' TYK2/JAK1 inhibitor scores phase 2 psoriasis win

May 21, 2025 6:25am